RISK INFORMATION SHEET

COMPANY NAME:	 	
ADVISER:		
TRANSACTION TYPE:		
CONTACT AT ADVISER:		
CONTACT FAX NUMBER		
MARKET CAPITALISATION:		
SIZE OF TRANSACTION:	 	
	 YES	NO
Details of transaction including any major or significant issues and any press articles of relevance.		
Contact made with monitoring in relation to disclosure rules prior to submission?		
If yes, name of contact:		
Contact made with Helpdesk/ Listing Transactions prior to submission?		
If yes, name of contact		
Any outstanding profit forecasts?		
Is the company a Regulated Entity?		
If yes, name of Supervisor		
Does the company have an Investment Manager?		
If yes, name of Manager		
Has the vetting fee been submitted?		
If yes please provide the date and method of payment (along with BACS reference details if applicable. Please note that comments will not be despatched until the payment has been received.		

The UKLA review documentation primarily from a prospectus rules/listing rules perspective. Comments raised will not necessarily cover all FSA aspects. If there is an assumption on rules other than the prospectus rules/listing rules then this should specifically be drawn to our attention. Please include details below of contact made with any other part of the FSA.	
Details and dates of approval of any transactions undertaken by the company in the last 12 months.	
Please confirm that the document submitted for review is substantially complete.	
Please ensure that this form is completed and submitted with the first draft of the Please also note all future correspondence in relation to the transaction will be on this Risk Information Sheet.	
You may find it useful to refer to the UK Listing Authorities fact sheet on "Dra offer prospectuses under the Prospectus Directive" which is available at http://www.fsa.gov.uk/pubs/ukla/factsheet3.pdf	fting and approval of public
Do not e mail the Risk Information Sheet. Please submit via ELS or by post wit	h the document.
SIGNED	
DATE	